RETECMA supplier risk profile Q1 2026: 71 shipments, 32 suppliers, India-focused pharma sourcing.
RETECMA processed 71 shipments across 32 suppliers in Q1 2026, sourcing from 9 countries spanning 30 HS codes. India led the import profile with 22 shipments (31% of total), followed by Italy with 15 shipments (21%). The importer's sourcing concentrated on pharmaceutical intermediates and plant extracts, with HS code 130219 (plant extracts) and 293729 (other organic compounds) each accounting for 6 shipments. Top suppliers included BIOFER (Italy, 6 shipments) and three Indian firms—FDC, SCL Lifesciences, and SNJ Lifecare Private—each contributing 4–5 shipments.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
One name matching against sanctions watchlists was detected in RETECMA's Q1 2026 supply chain. No suppliers registered proximity to forced-labor exposure under the Uyghur Forced Labor Prevention Act.
32 distinct tier-1 suppliers in Q1 2026
| BIOFER | Italy | 6 |
| FDC | India | 5 |
| SCL LIFESCIENCES | India | 5 |
| CSPC HEALTHCARE | United States | 4 |
| SNJ LIFECARE PRIVATE | India | 4 |
| FINZELBERG | Germany | 4 |
| MOEHS CATALANA S L | Spain | 3 |
| IFFECT CHEMPHAR | China | 3 |
Share of Q1 2026 inbound shipments by source country
93 tier-2 + 85 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.